Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model

Kazuhiko Kurozumi, Kiminori Nakamura, Takashi Tamiya, Yutaka Kawano, Keiji Ishii, Masayoshi Kobune, Sachie Hirai, Hiroaki Uchida, Katsunori Sasaki, Yoshinori Ito, Kazunori Kato, Osamu Honmou, Kiyohiro Houkin, Isao Date, Hirofumi Hamada

Research output: Contribution to journalArticle

339 Citations (Scopus)

Abstract

Mesenchymal stem cells (MSC) were reported to ameliorate functional deficits after stroke in rats, with some of this improvement possibly resulting from the action of cytokines secreted by these cells. To enhance such cytokine effects, we previously transfected the telomerized human MSC with the BDNF gene using a fiber-mutant adenovirus vector and reported that such treatment contributed to improved ischemic recovery in a rat transient middle cerebral artery occlusion (MCAO) model. In the present study, we investigated whether other cytokines in addition to BDNF, i.e., GDNF, CNTF, or NT3, might have a similar or greater effect in this model. Rats that received MSC-BDNF (P <0.05) or MSC-GDNF (P <0.05) showed significantly more functional recovery as demonstrated by improved behavioral test results and reduced ischemic damage on MRI than did control rats 7 and 14 days following MCAO. On the other hand, rats that received MSC-CNTF or MSC-NT3 showed neither functional recovery nor ischemic damage reduction compared to control rats. Thus, MSC transfected with the BDNF or GDNF gene resulted in improved function and reduced ischemic damage in a rat model of MCAO. These data suggest that gene-modified cell therapy may be a useful approach for the treatment of stroke.

Original languageEnglish
Pages (from-to)96-104
Number of pages9
JournalMolecular Therapy
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Middle Cerebral Artery Infarction
Nerve Growth Factors
Mesenchymal Stromal Cells
Brain-Derived Neurotrophic Factor
Glial Cell Line-Derived Neurotrophic Factor
Ciliary Neurotrophic Factor
Cytokines
Stroke
Genes
Cell- and Tissue-Based Therapy
Adenoviridae
Therapeutics

Keywords

  • Adenoviral vector
  • BDNF
  • Cerebral infarction
  • CNTF
  • GDNF
  • Gene therapy
  • Mesenchymal stem cell
  • MRI
  • NT3

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. / Kurozumi, Kazuhiko; Nakamura, Kiminori; Tamiya, Takashi; Kawano, Yutaka; Ishii, Keiji; Kobune, Masayoshi; Hirai, Sachie; Uchida, Hiroaki; Sasaki, Katsunori; Ito, Yoshinori; Kato, Kazunori; Honmou, Osamu; Houkin, Kiyohiro; Date, Isao; Hamada, Hirofumi.

In: Molecular Therapy, Vol. 11, No. 1, 01.2005, p. 96-104.

Research output: Contribution to journalArticle

Kurozumi, K, Nakamura, K, Tamiya, T, Kawano, Y, Ishii, K, Kobune, M, Hirai, S, Uchida, H, Sasaki, K, Ito, Y, Kato, K, Honmou, O, Houkin, K, Date, I & Hamada, H 2005, 'Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model', Molecular Therapy, vol. 11, no. 1, pp. 96-104. https://doi.org/10.1016/j.ymthe.2004.09.020
Kurozumi, Kazuhiko ; Nakamura, Kiminori ; Tamiya, Takashi ; Kawano, Yutaka ; Ishii, Keiji ; Kobune, Masayoshi ; Hirai, Sachie ; Uchida, Hiroaki ; Sasaki, Katsunori ; Ito, Yoshinori ; Kato, Kazunori ; Honmou, Osamu ; Houkin, Kiyohiro ; Date, Isao ; Hamada, Hirofumi. / Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. In: Molecular Therapy. 2005 ; Vol. 11, No. 1. pp. 96-104.
@article{40942a1a87914251a05d40f01287f205,
title = "Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model",
abstract = "Mesenchymal stem cells (MSC) were reported to ameliorate functional deficits after stroke in rats, with some of this improvement possibly resulting from the action of cytokines secreted by these cells. To enhance such cytokine effects, we previously transfected the telomerized human MSC with the BDNF gene using a fiber-mutant adenovirus vector and reported that such treatment contributed to improved ischemic recovery in a rat transient middle cerebral artery occlusion (MCAO) model. In the present study, we investigated whether other cytokines in addition to BDNF, i.e., GDNF, CNTF, or NT3, might have a similar or greater effect in this model. Rats that received MSC-BDNF (P <0.05) or MSC-GDNF (P <0.05) showed significantly more functional recovery as demonstrated by improved behavioral test results and reduced ischemic damage on MRI than did control rats 7 and 14 days following MCAO. On the other hand, rats that received MSC-CNTF or MSC-NT3 showed neither functional recovery nor ischemic damage reduction compared to control rats. Thus, MSC transfected with the BDNF or GDNF gene resulted in improved function and reduced ischemic damage in a rat model of MCAO. These data suggest that gene-modified cell therapy may be a useful approach for the treatment of stroke.",
keywords = "Adenoviral vector, BDNF, Cerebral infarction, CNTF, GDNF, Gene therapy, Mesenchymal stem cell, MRI, NT3",
author = "Kazuhiko Kurozumi and Kiminori Nakamura and Takashi Tamiya and Yutaka Kawano and Keiji Ishii and Masayoshi Kobune and Sachie Hirai and Hiroaki Uchida and Katsunori Sasaki and Yoshinori Ito and Kazunori Kato and Osamu Honmou and Kiyohiro Houkin and Isao Date and Hirofumi Hamada",
year = "2005",
month = "1",
doi = "10.1016/j.ymthe.2004.09.020",
language = "English",
volume = "11",
pages = "96--104",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model

AU - Kurozumi, Kazuhiko

AU - Nakamura, Kiminori

AU - Tamiya, Takashi

AU - Kawano, Yutaka

AU - Ishii, Keiji

AU - Kobune, Masayoshi

AU - Hirai, Sachie

AU - Uchida, Hiroaki

AU - Sasaki, Katsunori

AU - Ito, Yoshinori

AU - Kato, Kazunori

AU - Honmou, Osamu

AU - Houkin, Kiyohiro

AU - Date, Isao

AU - Hamada, Hirofumi

PY - 2005/1

Y1 - 2005/1

N2 - Mesenchymal stem cells (MSC) were reported to ameliorate functional deficits after stroke in rats, with some of this improvement possibly resulting from the action of cytokines secreted by these cells. To enhance such cytokine effects, we previously transfected the telomerized human MSC with the BDNF gene using a fiber-mutant adenovirus vector and reported that such treatment contributed to improved ischemic recovery in a rat transient middle cerebral artery occlusion (MCAO) model. In the present study, we investigated whether other cytokines in addition to BDNF, i.e., GDNF, CNTF, or NT3, might have a similar or greater effect in this model. Rats that received MSC-BDNF (P <0.05) or MSC-GDNF (P <0.05) showed significantly more functional recovery as demonstrated by improved behavioral test results and reduced ischemic damage on MRI than did control rats 7 and 14 days following MCAO. On the other hand, rats that received MSC-CNTF or MSC-NT3 showed neither functional recovery nor ischemic damage reduction compared to control rats. Thus, MSC transfected with the BDNF or GDNF gene resulted in improved function and reduced ischemic damage in a rat model of MCAO. These data suggest that gene-modified cell therapy may be a useful approach for the treatment of stroke.

AB - Mesenchymal stem cells (MSC) were reported to ameliorate functional deficits after stroke in rats, with some of this improvement possibly resulting from the action of cytokines secreted by these cells. To enhance such cytokine effects, we previously transfected the telomerized human MSC with the BDNF gene using a fiber-mutant adenovirus vector and reported that such treatment contributed to improved ischemic recovery in a rat transient middle cerebral artery occlusion (MCAO) model. In the present study, we investigated whether other cytokines in addition to BDNF, i.e., GDNF, CNTF, or NT3, might have a similar or greater effect in this model. Rats that received MSC-BDNF (P <0.05) or MSC-GDNF (P <0.05) showed significantly more functional recovery as demonstrated by improved behavioral test results and reduced ischemic damage on MRI than did control rats 7 and 14 days following MCAO. On the other hand, rats that received MSC-CNTF or MSC-NT3 showed neither functional recovery nor ischemic damage reduction compared to control rats. Thus, MSC transfected with the BDNF or GDNF gene resulted in improved function and reduced ischemic damage in a rat model of MCAO. These data suggest that gene-modified cell therapy may be a useful approach for the treatment of stroke.

KW - Adenoviral vector

KW - BDNF

KW - Cerebral infarction

KW - CNTF

KW - GDNF

KW - Gene therapy

KW - Mesenchymal stem cell

KW - MRI

KW - NT3

UR - http://www.scopus.com/inward/record.url?scp=19944406772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944406772&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2004.09.020

DO - 10.1016/j.ymthe.2004.09.020

M3 - Article

VL - 11

SP - 96

EP - 104

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -